Correlation between Hybrid Capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results: A cytologic/histologic review of 367 cases

Cancer Cytopathology

Volumn 118, Issue 4, 2010, Pages 209-217

  Knoepp, Stewart M ^a   Kuebler, Diane L ^b   Wilbur, David C ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cervical cytology; Human papillomavirus (HPV) testing; Hybrid Capture II; SurePath

Indexed keywords

VIRUS DNA;

ARTICLE; CHEMOLUMINESCENCE; FEMALE; FOLLOW UP; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; NUCLEIC ACID HYBRIDIZATION; PAPILLOMA VIRUS; PATHOLOGY; RISK; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VIROLOGY;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CHEMILUMINESCENT MEASUREMENTS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; NUCLEIC ACID HYBRIDIZATION; PAPILLOMAVIRIDAE; RISK; UTERINE CERVICAL NEOPLASMS;

EID: 78049513733     PISSN: None     EISSN: 19346638     Source Type: Journal    
DOI: 10.1002/cncy.20093     Document Type: Article

References (29)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
2. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001;84:1616-1623.
3. Stoler MH, Castle PE, Solomon D, Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007;127:335-337.
4. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342-350.
5. Munger K. Disruption of oncogene/tumor suppressor networks during human carcinogenesis. Cancer Invest. 2002;20:71-81.
6. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res. 2003;63:4862-4871.
7. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690-698.
8. Castle PE, Sideri M, Jeronimo J, Solomon D, Schiffman M. Risk assessment to guide the prevention of cervical cancer. Am J Obstet Gynecol. 2007;197:356 e1-6.
9. Goldie SJ, Kim JJ, Myers E. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine. 2006;24(suppl 3):S3/ 164-170.
10. Solomon D, Schiffman M, Tarone R. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001;93:293-299.
11. Solomon D, Schiffman M, Tarone R. ASCUS LSIL Triage Study (ALTS) conclusions reaffirmed: response to a November 2001 commentary. Obstet Gynecol. 2002;99:671-674.
12. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103: 619-631.
13. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007;197:340-345.
14. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006;119: 1095-1101.
15. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.
16. Kurtycz DF, Smith M, He R, Miyazaki K, Shalkham J. Comparison of methods trial for high-risk HPV. Diagn Cytopathol. 2010;38:104-108.
17. Ko V, Tambouret RH, Kuebler DL, Black-Schaffer WS, Wilbur DC. Human papillomavirus testing using hybrid capture II with SurePath collection: initial evaluation and longitudinal data provide clinical validation for this method. Cancer (Cancer Cytopathol). 2006;108:468-474.
18. Siddiqi A, Spataro M, McIntire H, et al. Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance papanicolaou results in SurePath and ThinPrep specimens. Cancer (Cancer Cytopathol). 2009;117:318-325.
19. Knoepp SM, Kuebler DL, Wilbur DC. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases. Diagn Mol Pathol. 2007;16:125-129.
20. Tsai HT, Wu CH, Lai HL, et al. Association between quantitative high-risk human papillomavirus DNA load and cervical intraepithelial neoplasm risk. Cancer Epidemiol Biomarkers Prev. 2005;14(11 pt 1):2544-2549.
21. Yuan Q, Wilbur DC. Original cervical cytology and follow- up biopsy results in positive high risk human papillomavirus DNA tests with high-level results. Acta Cytol. 2008;52:557-562.
22. Kuebler DL, Illingworth A, Blenc AM, Wilbur DC. A peer comparison program for the quality assurance of human papillomavirus DNA detection using the Digene Hybrid Capture II/SurePath method shows excellent analytic interlaboratory correlation. Cancer. 2007;111:339-343.
23. Federschneider JM, Yuan L, Brodsky J, Breslin G, Betensky RA, Crum CP. The borderline or weakly positive Hybrid Capture II HPV test: a statistical and comparative (PCR) analysis. Am J Obstet Gynecol. 2004;191:757-761.
24. Castle PE, Schiffman M, Scott DR, et al. Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1311-1314.
25. Jarboe EA, Venkat P, Hirsch MS, Cibas ES, Crum CP, Garner EO. A weakly positive HPV Hybrid Capture II result correlates with a significantly lower risk of HSIL following ASC-US cytology. Mod Pathol. 2008;21:207a- 208a.
26. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006;66:10112-10119.
27. Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet. 2002;360:228-229.
28. Sherman ME, Wang SS, Wheeler CM, et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev. 2003;12:1038-1044.
29. Sargent A, Bailey A, Turner A, et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J Clin Microbiol. 2010;48:554-558.